Related Experiment Video
Updated: Jun 12, 2025
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
From promise to progress: the dynamic landscape of glioblastoma immunotherapy
Muhammad Ijaz1, Zia Ullah2, Bilal Aslam3
1School of Science, Shenzhen Key Laboratory of Flexible Printed Electronics Technology, Shenzhen Key Laboratory of Advanced Functional Carbon Materials Research and Comprehensive Application, Harbin Institute of Technology, Shenzhen 518055, China; Institute of Microbiology, Government College University Faisalabad, Pakistan.
Abstract:
Glioblastoma multiforme (GBM) is the most common CNS cancer, it has dismal survival rates despite several effective mediators: intensified cytotoxic therapy, chimeric antigen receptor (CAR)-T cell therapy, viral therapy, adoptive cell therapy, immune checkpoint blockade therapy, radiation therapy and vaccine therapy. This review examines the basic concepts underlying immune targeting and examines products such as checkpoint blockade drugs, CAR-T cells, oncolytic viruses, combinatory multimodal immunotherapy and cancer vaccines. New approaches to overcoming current constraints and challenges in GBM therapy are discussed, based on recent studies into these tactics, findings from ongoing clinical trials, as well as previous trial results.
Insights
Glioblastoma multiforme (GBM) immunotherapy shows promise, exploring treatments like CAR-T cell therapy and oncolytic viruses. This review details current strategies and future directions for enhancing GBM treatment outcomes.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer Research
Background:
- Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor.
- Current GBM treatments yield poor survival rates.
- Despite advances, effective therapeutic strategies remain a challenge.
Purpose of the Study:
- To review the fundamental principles of immune targeting in GBM.
- To examine various immunotherapeutic agents and strategies.
- To discuss novel approaches for overcoming therapeutic challenges in GBM.
Main Methods:
- Comprehensive literature review of preclinical and clinical studies.
- Analysis of immune-targeting mechanisms in GBM.
- Evaluation of existing and emerging immunotherapies.
Main Results:
- Several immunotherapies show potential, including checkpoint blockade, CAR-T cell therapy, oncolytic viruses, and cancer vaccines.
- Combinatorial and multimodal approaches are being investigated.
- Ongoing clinical trials are evaluating novel therapeutic tactics.
Conclusions:
- Immunotherapy offers a promising avenue for improving GBM treatment.
- Overcoming resistance and enhancing efficacy requires innovative strategies.
- Further research and clinical trials are crucial for advancing GBM therapy.
